spacer
home > epc > autumn 2008 > all in the mind
PUBLICATIONS
European Pharmaceutical Contractor

All in the Mind

Animal models for CNS disorders have been shown to have limited predictive power for man, which in many cases is due to weaknesses in the animal models themselves. However, these models can often provide the information which is key to ensuring efficacy throughout formal preclinical development and Phase I clinical trials.

So, how can the investigator weigh up the strengths and weaknesses of different models in order for them to be used effectively so as to ensure that efficacy seen in animal studies translates into the clinic? This article will discuss the issues in relation to stroke, where a number of promising therapies have failed in the clinic, identifies broader relevance to other CNS conditions, and considers how to ensure that animal models enhance the prediction of efficacy in patients (1).

DEVELOPMENT OF THERAPIES FOR STROKE

Stroke is described as the rapid loss of brain function due to damage or a blockage of the blood vessels supplying blood to the brain, and can be due to a haemorrhage or ischaemia caused by thrombosis or embolism. Whilst these mechanisms all involve disruption of the blood supply to the brain, the range of mechanisms leading to disruption of blood flow and the extent of damage offers a range of potential therapeutic interventions, whilst making selection of the appropriate preclinical models more difficult (see Figures 2-4).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Peter Gaskin holds BSc in Biochemistry from the University of Surrey and a PhD from the University of Nottingham, and has worked in pharmaceutical R&D for over 19 years. He began his career working in mechanistic toxicology, drug metabolism and pharmacology at ICI’s central toxicology laboratory, followed by a number of posts in research and regulatory toxicology in the pharma and CRO industries. In 1999 Peter joined Quintiles, firstly as a Program Manager and subsequently as Associate Director and Head of Program Management. Following Aptuit’s acquisition of Quintiles preclinical business in 2005, Peter became a Principal Consultant in the newly-formed Aptuit Consulting Inc where he advises clients on non-clinical development strategies. He is a member of the British and European Toxicology Societies and a member of TOPRA.
spacer
Peter Gaskin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm’s CSO and University of Reading Professor co-author new book on dermal formulation development

MedPharm’s Chief Scientific Officer and Co-Founder, Professor Marc Brown and University of Reading’s Professor Adrian Williams have co-authored the new book: ‘The Art and Science of Dermal Formulation Development”. It is the latest addition to ‘Drugs and the Pharmaceutical Sciences’, a series of textbooks and monographs published by CRC Press.
More info >>

White Papers

Crunch Time: The Impact of Serialisation Requirements on Packaging Operations

PCI Pharma Services

The deadlines for including unique product identifiers on prescription drugs is putting a strain on multiple parts of the industry, much of which is ill-prepared to meet the target. Here, we look to the experience of a company that is ahead of the curve for lessons on how to manage and ease the transition to serialisation.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement